Manhattan Vision Screening and Follow-Up Study

Sponsor
Columbia University (Other)
Overall Status
Recruiting
CT.gov ID
NCT04271709
Collaborator
Centers for Disease Control and Prevention (U.S. Fed)
2,373
1
2
59.1
40.2

Study Details

Study Description

Brief Summary

The investigators are conducting a 5-year prospective, cluster-randomized controlled trial, funded by the Centers for Disease Control (CDC), which provides vision screenings to underserved, vulnerable New York City residents living in affordable housing buildings in Harlem and Washington Heights.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Enhanced Intervention Using Patient Navigators
  • Other: Usual Care
N/A

Detailed Description

This study aims to increase engagement, detection and management of glaucoma, vision impairment, cataracts, and other eye diseases in vulnerable populations living in New York City. This study considers disparities by race, ethnicity, gender, geography, and socioeconomic status using innovative approaches such as patient navigators. Individuals over the age of 40 living in New York City Housing Authority (NYCHA) Housing buildings are eligible.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
2373 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Screening
Official Title:
The Manhattan Vision Screening and Follow-Up Study in Vulnerable Populations
Actual Study Start Date :
Sep 30, 2019
Anticipated Primary Completion Date :
Sep 1, 2024
Anticipated Study Completion Date :
Sep 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Enhanced Intervention

Consented subjects living in buildings randomized to the Enhanced Intervention arm who fail the screening and need vision correction will receive free eyeglasses, which will be fitted by an optician at the housing building. If they are referred to an ophthalmologist for a follow-up eye exam, they will receive enhanced support with patient navigators to assist with all aspects of follow-up eye care and ocular surgery at either Harkness Eye Institute or Harlem Hospital, specifically eye exam appointment scheduling and arranging transportation over a 1-year period.

Behavioral: Enhanced Intervention Using Patient Navigators
Enhanced support includes patient navigators to assist with all aspects of follow-up eye care and ocular surgery at either Harkness Eye Institute or Harlem Hospital, specifically eye exam appointment scheduling and arranging transportation over a 1-year period.

Placebo Comparator: Usual Care

Consented subjects living in buildings randomized to Usual Care arm who fail the screening and need vision correction will be given an eyeglasses prescription and a list of optical shops within 1 mile from their home. These subjects who are referred to an ophthalmologist for a follow-up eye exam will only be scheduled for their initial appointment at either Harkness Eye Institute or Harlem Hospital. They will not receive enhanced support. Scheduling this initial appointment will allow tracking of adherence.

Other: Usual Care
Usual Care subjects who fail the screening and need vision correction will be given an eyeglasses prescription and a list of optical shops within 1 mile from their home. These subjects who are referred to an ophthalmologist for a follow-up eye exam will only be scheduled for their initial appointment at either Harkness Eye Institute or Harlem Hospital. They will not receive enhanced support. Scheduling this initial appointment will allow tracking of adherence.

Outcome Measures

Primary Outcome Measures

  1. Proportion of Subjects with Visual Acuity Worse than 20/40 [2 years]

    Visual acuity (VA) is a measure of the spatial resolution of the visual processing system. Visual acuity will be measured in each eye and measured as ≤20/40 or >20/40. Since there are two best corrected distance visual acuity measurements per person (right eye and left eye), the visual acuity in the worse eye will be used in the analysis and reported at the patient level, rather than the eye level. Visual acuity analysis will be handled as a dichotomous variable and the proportion of subjects with visual acuity 20/40 or worse will be considered abnormal.

Eligibility Criteria

Criteria

Ages Eligible for Study:
40 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Individuals over age 40

  • Living independently in NYCHA housing building.

  • Willing to answer COVID-19 symptom questions

  • Willing to consent for 2 vision screening visits at baseline and 12-month follow-up

Exclusion Criteria:
  • Self-reported terminal illness with life expectancy less than 1 year

  • Inability to provide informed consent due to dementia or other reasons

Contacts and Locations

Locations

Site City State Country Postal Code
1 Columbia University New York New York United States 10032

Sponsors and Collaborators

  • Columbia University
  • Centers for Disease Control and Prevention

Investigators

  • Principal Investigator: Lisa A. Hark, PhD, RD, Columbia University

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Lisa Hark, Professor of Ophthalmic Sciences, Columbia University
ClinicalTrials.gov Identifier:
NCT04271709
Other Study ID Numbers:
  • AAAR9162
  • U01DP006436
First Posted:
Feb 17, 2020
Last Update Posted:
Aug 2, 2021
Last Verified:
Jul 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Lisa Hark, Professor of Ophthalmic Sciences, Columbia University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 2, 2021